Moderna, Novavax shares also pressured after hours
Pfizer Inc. PFE, -2.46% shares dropped in the extended session Friday after the drug maker slashed its full-year outlook due to COVID product write offs. Pfizer shares dropped more than 7% after hours, following a 2.
5% decline to close the regular session at $32.11. The company forecast full-year earnings of $1.45 to $1.65 a share on revenue of $58 billion to $61 billion. Analysts surveyed by FactSet expect $3.29 a share on revenue of $65.96 billion.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Harris County Public Health offering updated Pfizer-BioNTech, Moderna COVID-19 vaccinesAccording to HCPH, the updated vaccine is free for those six months and older without health insurance or whose insurance does not cover all COVID-19 vaccine costs.
Read more »
Pfizer’s stock sinks after company cuts outlook on lower demand for COVID productsWallace Witkowski came to MarketWatch from the Associated Press in New York, where he covered the business of Big Pharma, after covering FDA regulation of many of the same companies, as well as medical devices, in the Washington, D.C., area.
Read more »
Travis Kelce’s ‘Mr Pfizer’ gig stirs debate about COVID vax messagingKansas City Chiefs star Travis Kelce's recent partnership with pharmaceutical giant Pfizer has stirred a debate about COVID-19 vaccine messaging.
Read more »
Pfizer slashes 2023 revenue forecast on lower COVID sales; will cut expenses, jobsPfizer (PFE.N) on Friday slashed its full-year revenue forecast by around 13% and launched a $3.5 billion cost cutting program due to lower-than-expected sales of its COVID-19 vaccine and treatment.
Read more »
Pfizer slashes 2023 revenue forecast on lower COVID sales; will cut expenses, jobsPfizer slashes 2023 revenue forecast on lower COVID sales; will cut expenses, jobs
Read more »
FDA approves Pfizer’s Braftovi plus Mektovi for a type of non-small cell lung cancerCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Read more »